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Abstract: Management of oral candidosis, most frequently caused by Candida albicans, is limited 
due to the relatively low number of antifungal drugs and the emergence of antifungal tolerance. 
In this study, the antifungal activity of a range of commercial essential oils, two terpenes, 
chlorhexidine and triclosan was evaluated against C. albicans in planktonic and biofilm form. In 
addition, cytotoxicity of the most promising compounds was assessed using murine fibroblasts 
and expressed as half maximal inhibitory concentrations (IC50). Antifungal activity was 
determined using a broth microdilution assay. The minimum inhibitory concentration (MIC) was 
established against planktonic cells cultured in a range of concentrations of the test agents. The 
minimal biofilm eradication concentration (MBEC) was determined by measuring re-growth of 
cells after pre-formed biofilm was treated for 24 h with the test agents. All tested commercial 
essential oils demonstrated anticandidal activity (MICs from 0.06% (v/v) to 0.4% (v/v)) against 
planktonic cultures, with a noticeable increase in resistance exhibited by biofilms (MBECs >1.5% 
(v/v)). The IC50s of the commercial essential oils were lower than the MICs, while a one hour 
application of chlorhexidine was not cytotoxic at concentrations lower than the MIC. In 
conclusion, the tested commercial essential oils exhibit potential as therapeutic agents against C. 
albicans, although host cell cytotoxicity is a consideration when developing these new treatments.   
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1. Introduction 
Candida are commensal fungal microorganisms that can colonise the oral cavity, where they are 
mainly found on the posterior part of the tongue and the oral mucosa. Changes in the oral 
environment that lead to increased Candida growth can instigate oral candidosis [1]. The rising 
number of immunocompromised and immunodeficient patients has resulted in an increased 
incidence of fungal infections. To highlight this, Candida-related infections affect 65% of HIV 
positive individuals and over 80% of AIDS patients [2Ȯ4]. The higher life expectancy of the 
general population has also led to a rise in denture wearing, with a concomitant increase in 
Candida-associated stomatitis [5Ȯ7]. Even though more than 17 Candida species can cause human 
infection, oral candidosis are mainly caused by C. albicans [8]. In the mouth, Candida typically 
grows as biofilms, which are three-dimensional structures attached to surfaces including human 
tissue or abiotic substrates (e.g. a denture). Biofilm cells are embedded in a self-produced 
extracellular polymeric matrix and importantly often exhibit an elevated tolerance to 
antimicrobial agents and host defences [5]. 
Current therapies for oral candidosis include use of topical or systemic antifungal agents, such as 
polyenes and azoles. Polyenes (e.g. nystatin and amphotericin B) are fungicidal through binding 
to ergosterol in the fungal cell membrane and inducing cell membrane damage. Azoles, such as 
fluconazole and miconazole, are fungistatic by inhibiting the enzyme lanosterol demethylase, 
involved in ergosterol biosynthesis [9]. Importantly, the range of available antifungals are limited 
compared to antibiotics [9], and coupled with the rise of Candida resistance, especially within 
biofilms, this has led to an interest in the discovery of new antifungal compounds [10].  
Essential oils are natural products produced by aromatic plants and are mainly composed by 
terpenes and terpenoids [11]. Being lipophilic, these oils typically integrate into membrane 
structures causing increased cell permeability, leaching of intracellular components and 
inactivation of enzymes [12,13]. Essential oils can act against Candida by inhibiting ergosterol 
synthesis [14Ȯ18], altering cell wall morphology [15,17Ȯ19], inhibiting enzymes involved in cell 
wall synthesis [18,20], changing cell membrane permeability [21,22] and producing oxygen 
reactive species [23]. Furthermore, essential oils can also interact with the mitochondrial 
membrane leading to cidal effects [11]. Antimicrobial, anti-aseptic, anti-inflammation and anti-
oxidant activity of essential oils, alone and in combination with commercial agents is well known 
[13,24Ȯ26]. However, limited knowledge exists regarding essential oil activity against biofilms 
and also host cell cytotoxicity.  
The aim of this study was therefore to investigate the antifungal potential of twelve commercial 
essential oils and two terpenes (E-cinnamaldehyde and linalool) against C. albicans planktonic 
and biofilm growth. The cytotoxicity of the most active commercial essential oils was established 
against mouse fibroblasts. Antifungal activity of commercial essential oils was compared to 
chlorhexidine (CHX) and triclosan. These two biocides have previously shown antimicrobial 
properties against a wide range of oral pathogens and are frequent components in mouthwashes 
and toothpastes [27, 28].  
 
2. Results  
2.1. Minimum inhibitory concentration (MIC) 80 and minimal lethal concentration 
The minimum inhibitory concentration (MIC) 80 of the test agents against C. albicans NCYC 1363 
and C. albicans 135BM2/94 are shown in Table 1. The commercial essential oils that inhibited the 
growth at the lowest concentrations were melissa and geraniol, while myrtle and sage had the 
lowest fungistatic potential (p<0.001).  
 
Table 1 - Minimum inhibitory concentration 80 of commercial essential oils and biocides 
against C. albicans NYCY 1363 and C. albicans 135BM2/94 in the planktonic form  
 
 Minimum inhibitory concentration 80 [% (v/v)] [(g/L)] 
Antimicrobial C. albicans NYCY 1363 C. albicans 135BM2/94 
Basil 0.1 (0.9) 0.1 (0.9) 
Bergamot 0.3 (2.6) 0.3 (2.6) 
Cinnamon 0.1 (1.0) 0.1 (1.0) 
Citronella 0.1 (0.9) 0.1 (0.9) 
Geranium 0.07 (0.6) 0.06 (0.5) 
Lavander 0.2 (1.8) 0.1 (0.9) 
Melissa 0.06 (0.5) 0.06 (0.5) 
Myrtle 0.4 (3.5) 0.3 (2.7) 
Peppermint 0.1 (0.9) 0.1 (0.9) 
Sage 0.4 (3.7) 0.3 (2.7) 
Spearmint 0.2 (1.6) 0.1 (1.1) 
Tea tree oil 0.2 (1.8) 0.2 (1.8) 
E-cinnamaldehyde 0.03 (0.3) 0.01 (0.1) 
Linalool 0.1 (0.9) 0.1 (0.9) 
CHX 2  10-3 (2.1  10-2) 5  10-3 (5.3  10-2) 
Triclosan 5.66  10-4 (8.4  10-3) 5.89  10-4 (8.8  10-3) 
 
Minimal inhibitory concentration 80 (MIC80) defined as the lowest concentration of the 
antimicrobial agent that led to 80% reduction in absorbance compared to controls without 
agent. MIC values are in % (v/v) and in brackets are the equivalent MIC values in (g/L). 
 
Fungicidal activity was also expressed as the lowest concentration of antimicrobial agent that 
killed the microorganism (minimal lethal concentration) (Table 2). All tested compounds, with 
exception of triclosan, had minimal lethal concentrations against C. albicans at tested 
concentrations. However, these lethal concentrations were generally higher than the previously 
established MICs.  
 
Table 2 - Minimal lethal concentration of commercial essential oils and biocides against C. 
albicans NYCY 1363 and C. albicans 135BM2/94 in the planktonic growth mode 
 
 Minimal lethal concentration [% (v/v)] [(g/L)] 
Antimicrobial  C. albicans NCYC 1363 C. albicans 135BM2/94 
Basil 0.5 (4.5) 0.5 (4.5) 
Bergamot 0.5 (4.4) 0.5 (4.4) 
Cinnamon 0.1 (1.0) 0.1 (1.0) 
Citronella 0.1 (0.9) 0.1 (2.7) 
Geranium 0.1 (0.9) 0.1 (0.9) 
Lavander 0.5 (4.4) 0.3 (2.6) 
Melissa 0.1 (0.9) 0.1 (0.9) 
Myrtle 1 (8.8) 1 (8.8) 
Peppermint 0.3 (2.7) 0.1 (0.9) 
Sage 1 (9.2) 1 (9.2) 
Spearmint 1 (9.2) 1 (9.2) 
Tea tree oil 0.5 (4.5) 0.3 (2.7) 
E-cinnamaldehyde 0.03 (0.3) 0.03 (0.3) 
Linalool 0.3 (2.6) 0.3 (2.6) 
CHX 2.5  10-3 (2.7  10-2) 5  10-3 (5.3  10-2) 
Triclosan NA NA 
 
Minimal lethal concentration was defined as the lowest concentration of the antimicrobial agent 
that killed C. albicans. MLC values are in % (v/v) and in brackets are the equivalent MLC values 
in (g/L). NA = no antimicrobial activity at tested concentrations. 
 
2.2. Minimal biofilm eradication concentration 80  
The antifungal activity of biocides and commercial essential oils against C. albicans biofilms was 
expressed as the minimal biofilm eradication concentration (MBEC) [29]. Most test agents were 
not active against biofilms at tested concentrations and did not prevent regrowth after removal 
of the antimicrobial (Table 3). The antimicrobials that exhibited an MBEC against both tested C. 
albicans strains were melissa geranium, E-cinnamaldehyde and linalool (Table 3). 
 
  
Table 3 Ȯ Minimal biofilm eradication concentration 80 of commercial essential oils and 
biocides against C. albicans NCYC 1363 and C. albicans 135BM2/94  
 
 Minimal biofilm eradication concentration 80 [% (v/v)] [(g/L)] 
Antimicrobial C. albicans NYCY 1363 C. albicans 135BM2/94 
Basil NA NA 
Bergamot NA NA 
Cinnamon NA NA 
Citronella NA NA 
Geranium 2.5 (22.3) 2 (17.9) 
Lavander NA NA 
Melissa 1.5 (13.3) 1.5 (13.3) 
Myrtle NA NA 
Peppermint NA NA 
Sage NA NA 
Spearmint NA NA 
Tea tree oil NA NA 
E-cinnamaldehyde 0.8 (8.4) 0.8 (8.4) 
Linalool 1 (8.7) 1.5 (13.1) 
CHX 0.07 NA 
Triclosan > 5  10-3 (7.45  10-2) > 5  10-3 (7.45  10-2) 
 
Minimal biofilm eradication concentration 80 (MBEC80) defined as the lowest antimicrobial 
concentration that prevented at least 80% regrowth of Candida, after the biofilm was treated 
with antimicrobials for 24 h. MBEC values are in % (v/v) and in brackets are the equivalent 
MBEC values in (g/L). NA = no antimicrobial activity at tested concentrations. 
 
2.3. Half maximal inhibitory concentration (IC50) against fibroblasts 
The half maximal inhibitory concentration (IC50) CHX, cinnamon, E-cinnamaldehyde, geranium 
and melissa on fibroblast proliferation after a 1 h and 24 h exposure was determined (Figure 1; 
Table 4). The highest cytotoxicity occurred with E-cinnamaldehyde, followed by geranium 
(p<0.0001), which halved proliferation even at the lowest concentration tested. Indeed, a 
concentration of 0.003% (v/v) E- cinnamaldehyde and 0.01% (v/v) geranium inhibited 50% of cell 
proliferation (Table 4). Melissa was the least cytotoxic commercial essential oil, halving 
proliferation at 0.03% (v/v) (p<0.0001). A 1 h exposure of fibroblasts to cinnamon resulted in 
similar cytotoxicity as melissa, but prolonged exposure led to higher cytotoxicity (p<0.0001). A 1 
h application of CHX was cytotoxic only at the highest concentration tested (IC50 of 0.01% (v/v)) 
which was higher than the MIC, while a 24 h exposure at 7  10-4 % (v/v) was sufficient to halve 
fibroblast proliferation.  
 
 
 
 
 
 
 
Figure 1 Ȯ Cytotoxicity of selected antimicrobials against murine fibroblasts.  
Fibroblast numbers (normalised by the control (0% (v/v) antimicrobial) after a 1 h (red square) 
and 24 h application (blue circle) of CHX (A), cinnamon (B), E-cinnamaldehyde (C), geranium 
(D) and melissa (E) 
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 Table 4 Ȯ Half maximal inhibitory concentration (IC50) against fibroblasts after 1 h and 24 h 
application of the antimicrobial 
 
 Half maximal inhibitory concentration [% (v/v)] [(g/L)] 
Antimicrobial  1 h 24 h 
Cinnamon 0.03 (0.36) 0.01 (0.11) 
Geranium 0.01 (0.08) 0.01 (0.07) 
Melissa 0.03 (0.3) 0.03 (0.3) 
E-cinnamaldehyde 0.003 (0.03) 0.002 (0.02) 
CHX 0.01 (0.15) 7.32  10-4 (0.008) 
 
Half maximal inhibitory concentration (IC50) defined as the antimicrobial concentration that 
inhibits the 50% of cell proliferation compared to controls without agent. IC50 values are in % 
(v/v) and in brackets are the equivalent IC50 values in (g/L). 
 
 
3. Discussion 
Essential oils are natural products often extracted from plants, and they frequently exhibit 
antimicrobial, anti-aseptic, anti-inflammatory and anti-oxidant activities. The primary aim of this 
research was to evaluate the antifungal activity of 12 commercial essential oils against C. albicans. 
All tested commercial essential oils demonstrated antifungal activity against planktonic C. 
albicans, with MICs ranging from 0.06% (v/v) to 0.4% (v/v), and MLCs from 0.1% (v/v) to 1% (v/v). 
Comparison of results with those of other studies is problematic given differences in assay 
techniques [30, 31]. In addition, the botanical source, climate and environmental conditions, time 
of harvesting and extraction method can effect both composition and antimicrobial activity of 
commercial essential oils [31Ȯ33].  
The effect of plant origin on antimicrobial properties can be appreciated by comparing the activity 
of cinnamon oil extracted from Cinnamomum zeylanicum leaves and Cinnamomum aromaticum 
leaves. Both types of cinnamon oils are from the evergreen cinnamomum plant, but Cinnamomum 
aromaticum extract contains a higher amount of E-cinnamaldehyde, which could explain the 
higher antifungal activity (MICs 0.0006% (v/v) - 0.0096% (v/v)) [32] compared to the present study 
using Cinnamomum zeylanicum (MIC 0.1% (v/v)) extract. The impact that the amount of E-
cinnamaldehyde has on antifungal properties of an essential oil was also evident in this study 
(MICs of 0.03% (v/v) and 0.01% (v/v)). Geranium and melissa oils exhibited highest antifungal 
potential. Both commercial oils contain geraniol and citronellol, which are antifungal [34], and 
likely responsible for the similar antifungal activity of these oils (p>0.90). However, the MIC of 
melissa oil was lower than that previously reported [35,36]. This present study revealed 
antifungal effects for bergamot oil (MIC of 0.3% (v/v) and MLC of 0.5% (v/v)) which has 
previously only had limited attention. The MIC of basil oil 0.1% (v/v) (0.9 g/L) was lower than 
previously reported, namely 0.5% (v/v) [30] and 0.312% (v/v) [32], but comparable to the MIC 
(ŗŘśŖ μg/ml) found against a fluconazole resistant C. albicans strain [15]. The main compound of 
basil and lavender oils is linalool, which previously has had MICs ranging from 0.06% (v/v) to 
0.12% (v/v) [37]. Comparing activity of pure linalool to those of basil and lavender oils, the 
anticandidal activity of terpene was not significantly higher than that of basil (p>0.99). Tea tree 
oil had an MIC of 0.2% (v/v), and this was similar to that recorded by Hammer et al. against C. 
albicans [38]. Sage oil exhibited MICs of 0.3% (v/v) (2.7 g/L) and 0.4% (v/v) (3.7 g/L), which were 
comparable to the MIC of 2.78 g/l reported using a disk diffusion method [39], but lower than the 
MIC of 1.32 mg/ml measured by broth microdilution assay [40]. Despite their differences in 
composition, peppermint and spearmint oils had similar antifungal activities with MICs of 0.1% 
(v/v) and 0.1% (v/v) - 0.2% (v/v), respectively (p>0.07). However, while the MICs of spearmint oil 
were similar to those reported by Hammer et al. [30], the MIC of peppermint oil was higher than 
that found by Those et al. [41]. Myrtle oil had the lowest antifungal potential, even though its 
MICs were lower than those previously reported by Mahboubi et al. (MIC of 0.8-1.6% (v/v)) [42]. 
CHX and triclosan, two biocides whose antimicrobial properties are widely recognised and both 
commonly added to mouthwashes and toothpastes, were also evaluated in this study. Triclosan 
exhibited fungistatic activity only at concentrations higher than those used in toothpaste 
formulations (0.3% (w/v) [43]), but did not exhibit fungicidal effects at tested concentrations.  
The majority of agents had limited antibiofilm activity. Bacteria in biofilms can be between 10 
and 1000 times more tolerant to antibiotics than their planktonic counterparts, and similar 
findings have been reported for Candida [44]. The mechanisms by which biofilm cells have 
elevated antimicrobial tolerance are complex and likely multifactorial. These include altered gene 
expression following surface attachment, reduced growth rates in biofilms, variable nutrient 
availability that induces changes in phenotype, and the presence of extracellular polymeric 
substances that impedes penetration of agents into the biofilm [45]. Few studies have previously 
reported activity of commercial essential oils or biocides against C. albicans biofilms [46,47]. In the 
present study, from melissa oil, geranium oil, E-cinnamaldehyde and linalool all had anti-biofilm 
activity, whilst CHX only had anti-biofilm activity against C. albicans NCYC 1363. A 3 min 
application of cinnamon (1 mg/ml) and citronella (1 mg/ml) oils has been found to reduce biofilm 
cell numbers immediately after treatment, but this effect was not evident 48 h post treatment [46]. 
These results concur with the current study, where no antibiofilm activity was noted for 
cinnamon and citronella oils after 24 h. An MBEC of tea tree oil of 12.5% (v/v) had previously 
been reported [47], which is a higher concentration (8% (v/v)) than tested in this study, as 
difficulties were encountered in forming a stable suspension of the oil-medium using 1% (v/v) 
Tween 80.  
Few studies have investigated the cytotoxic effects of these oils. Cytotoxicity of CHX, cinnamon, 
E-cinnamaldehyde, geranium and melissa oils had a dose- and time-dependent cytotoxicity. 
Overall, the commercial essential oils halved fibroblast proliferation at concentrations lower than 
their MICs. The IC50 values for E-cinnamaldehyde, geranium and cinnamon oils were actually 
10-fold lower than their MIC 80, while melissa oil had an MIC 80 of 0.06% (v/v) and an IC50 of 
0.03% (v/v). Although a different assay and cell type was used, the melissa oil results (IC50 0.3 
g/L) were in accordance with those of Paul et al. [48] who did not see a significant change in 
leukocytes viability after ř h treatment with ŗśŖ μg/ml melissa oil. Several studies have used E-
cinnamaldehyde to inhibit proliferation of cancer cells and reported IC50s ranging from 45.8 to 
129.4 mM [49], higher than those obtained in this study with fibroblasts (0.16 Ȯ 0.26 mM). Barros 
et al. found that at concentrations lower than those evaluated in this study (5 µg/ml), 
Cinnamomum zeylanicum oil had cytoxicity towards erythrocytes [50]. A 1 h exposure of fibroblasts 
to CHX (0.01% (v/v)) halved cell proliferation compared to controls. However, this concentration 
was lower than the MICs (2.5  10-3 %(v/v) and 5  10-3 %(v/v)) found in the current study. This 
finding was similar to the cytotoxic effect of CHX previously reported using macrophages [51] 
and human alveolar bone cells [52]. Even if these results showed that commercial essential oils 
were cytotoxic, it should be taken into account that cytotoxicity was conducted in 2D culture, 
which is notably different from in vivo conditions. Further investigation on mammalian cells 
could be performed in 3D culture or ex/in vivo models to better mimic the biological structure of 
the tissues. 
 
4. Materials and methods 
4.1. Essential oils and biocides preparation 
Twelve commercial essential oils (Essential Oils Direct Ltd., Oldham, UK) (Table 5), two terpenes 
(E-cinnamaldehyde and linalool (Sigma-Aldrich, Gillingham, UK)), chlorhexidine digluconate 
(CHX) (Sigma-Aldrich, Gillingham, UK) and triclosan (Irgasan from Sigma-Aldrich, Gillingham, 
UK) were evaluated.  
 
Table 5 Ȯ List of commercial essential oils tested 
 
Plant species Essential oil Origin  
Ocimum basilicum Basil oil Leaves 
Citrus bergamia Bergamot FCF oil Peel 
Cinnamomum zeylanicum Cinnamon leaf oil Leaves 
Cymbopogon winterianus Citronella oil  Aerial parts 
Pelargonium graveolens Geranium oil Flowering herb 
Lavandula angustifolia Lavander oil Flowering herb 
Melissa officinalis Melissa oil Leaves and tops 
Myrtus communis Myrtle oil Leaves 
Mentha piperita Peppermint oil Whole plant 
Salvia officinalis Sage oil Leaves 
Mentha spicata Spearmint oil  Aerial parts 
Melaleuca alternifolia Tea tree oil Leaves and twigs  
The commercial essential oils were tested at a range of concentrations against planktonic growth 
(2% (v/v) to 0.007% (v/v) and biofilms (8% (v/v) to 0.125% (v/v)). All agents were prepared in 
Sabouraud Dextrose Broth (SDB; Oxoid, Basingstoke, UK). To enhance dispersion of essential oils 
in the medium, 1% (v/v) Tween 80 (Sigma-Aldrich, Gillingham, UK) was added. In the case of 
biofilm studies, 0.015% (w/v) Agar Bacteriological (LP0011 Oxoid) was added to SDB [53]. CHX 
was used in SDB at concentrations between 0.04% (v/v) to 3.1  10-4 % (v/v) and from 0.08% (v/v) 
to 6.2  10-4 % (v/v) for planktonic and biofilm growth experiments, respectively. A 20% (w/v) 
stock solution of triclosan was prepared in Dimethyl Sulfoxide (DMSO) (Fisher Chemical, 
Loughborough, UK). Serial doubling dilutions of the stock solution were prepared in SDB 
yielding final concentrations from 5.2  10-6% (v/v) to 6.7  10-4% (v/v) and from 1.7  10-4% (v/v) 
to 5  10-3 (v/v) for planktonic and biofilm experiments, respectively.  
 
Microorganisms 
Candida albicans NYCY 1363 and C. albicans 135BM2/94 were used to assess antifungal activity of 
commercial essential oils and biocides. Candida albicans 135BM2/94 is a clinical strain from the 
School of Dentistry (Cardiff University), which has been described as a high invader of tissues 
[54]. Strains were subcultured onto Sabouraud Dextrose Agar (SDA) (CM0041 Oxoid) and grown 
at 37°C in an aerobic incubator for 24 h. A colony of C. albicans was inoculated in 20 ml of SDB and 
incubated aerobically with shaking (150 rev/min) overnight at 37°C. The overnight culture was 
prepared in SDB to a turbidity equivalent to a 0.5 McFarland Standard and used for further 
experiments.  
 
Minimum inhibitory concentration and minimal lethal concentration 
The minimum inhibitory concentration (MIC) and the minimal lethal concentration (MLC) were 
determined using a broth microdilution assay. The method was adapted from that previously 
reported by Malic et al. [29]. Briefly, 100 µl of antimicrobial and 100 µl of overnight culture diluted 
to 1  105 CFU/ml were added to the wells of 96-well microtitre plates (Thermo Fisher Scientific, 
Hemel Hempstead, UK). Controls included Candida suspension cultured in SDB, with or without 
0.5% (v/v) of Tween 80. In addition, when triclosan was tested, SDB containing 1% (v/v) DMSO 
was used as control. The plates were covered with the lids supplied by the manufacturer and 
sprayed with 3% (v/v) of Triton 100-X (Sigma-Aldrich, Gillingham, UK) in pure ethanol to reduce 
condensation. The plates were incubated aerobically at 37°C with shaking at 110 rpm, for 24 h. 
Growth was estimated by measuring turbidity of each well by spectrophotometric absorbance at 
ŜŘŖ nm ǻThermo Scientific™ Multiskan™ GO Microplate SpectrophotometerǼ, shaking ř s before 
the reading. The absorbance readings were standardised against microbial-free controls. The 
minimal inhibitory concentration 80 (MIC 80) was defined as the lowest concentration of the 
antimicrobial agent that showed at least 80% reduction in absorbance compared to the control. 
The MLC was determined by plating selected well contents (where no visible growth was 
evident) on to SDA and incubating for 24 h at 37°C. The MLC was defined as the lowest 
concentration of antimicrobial agent that killed the Candida as shown by no colony growth on 
SDA. All concentrations were tested in quadruplicate and on three separate occasions.  
 
Minimal biofilm eradication concentration 80 
The minimal biofilm eradication concentration (MBEC) method was adapted from Malic et al. 
(2013) [29]. Briefly, a 96-well microtitre plate containing 200 µl of an overnight culture diluted at 
1  105 CFU/ml was incubated for 48 h at 37 °C without agitation to allow biofilm formation. 
Controls included Candida suspension cultured in SDB, with or without 1% (v/v) of Tween 80 and 
0.015% (w/v) Agar Bacteriological. When triclosan was tested, SDB containing 8% (v/v) DMSO 
was also used as control. After 48 h, the SDB was removed and the microtitre plate inverted onto 
tissue paper to remove residual medium. The biofilm was washed three times with 100 µl of PBS. 
One hundred µl of test agent was added to the biofilm and the plate incubated statically for 24 h 
at 37 °C. After incubation, test agent was removed and the biofilm washed twice with 100 µl of 
PBS. Two hundred µl of SDB was added to each well and the biofilm disrupted by repeated 
pipetting. The three replicates were then pipetted into a microcentrifuge tube which was then 
centrifuged for 3 min at 3000 rev/min (Hettich Universal Mikro 12Ȯ24, Hettich, Tuttlingen, 
Germany). The supernatant containing residual test agent was discarded and the microorganisms 
resuspended in fresh SDB and three wells of a 96-well plate were inoculated with the suspension. 
The turbidity of the suspension was measured by spectrophotometer absorbance at 620 nm prior 
to and after incubation for 24 h at 37 °C with shaking at 110 rev/min. The minimal biofilm 
eradication concentration 80 (MBEC80) was defined as the lowest antimicrobial concentration 
that prevented at least 80% regrowth of Candida. All experiments were conducted on three 
separate occasions.  
 
Half maximal inhibitory concentration  
Mouse fibroblasts (NIH 3T3; Sigma-Aldrich, Gillingham, UK) were cultured in Dulbecco 
Modified Eagle Medium (DMEM, Sigma) supplemented with 10% (v/v) fetal bovine serum (FBS) 
(Gibco, BRL), 1% (v/v) penicillin/streptomycin (Sigma-Aldrich, Gillingham, UK) and 1% (v/v) L-
glutamine (Sigma-Aldrich, Gillingham, UK). Serial doubling dilutions of commercial essential 
oils and biocides were prepared in the fibroblast culture medium at final concentrations ranging 
from 0.25% to 0.007% (v/v) for the commercial essential oils and from 0.04% to 3  10-4 % (v/v) for 
chlorhexidine. Fibroblasts were harvested using trypsin EDTA (EDTA 0.25% (w/v), Trypsin 0.53 
mM, Thermo Fisher Scientific, Hemel Hempstead, UK) and diluted to a density of 5  105 cells/ml. 
One-hundred µl of the cell suspension was used to inoculate a 96-well plate (5  104 cells per well) 
which was then incubated at 37°C and 5% CO2 for 1.5 h. A 100-µl volume of the antimicrobial 
was then added. After 1 and 24 h, the medium was removed and the cells washed twice with 100 
µl of PBS. Three hundred µl of DMEM containing 10% (v/v) of alamarBlue (AlamarBlue Cell 
Viability Reagent, Invitrogen) was added to each well and the plate incubated for 1.5 h. 
Fluorescence was read with a Synergy HT plate reader (BioTek® Instruments, Winooski, VT, 
USA) with excitation and emission wavelengths of 545 nm and 590 nm, respectively. The half 
maximal inhibitory concentration (IC50) was defined as the antimicrobial concentration that 
inhibited 50% cell proliferation compared to the control (i.e. DMEM without antimicrobial agent). 
Each condition was studied in triplicate and on three separate occasions. 
 
Statistical analysis  
Statistical analysis was performed using GraphPad Prism version 7.0. Data were presented as 
arithmetic mean ± SD. The difference between treatments was statistically analysed using one-
way analysis of variance (ANOVA) followed by Tukey multiple comparisons test. Statistically 
significant differences were set at p < 0.05. 
 
 
Conclusion 
This study showed that all the twelve commercial essential oils, two terpenes and triclosan and 
CHX had antifungal activity against planktonic C. albicans. Six of these compounds (CHX, 
cinnamon, E-cinnamaldehyde, linalool, geranium and melissa) were also active against C. albicans 
biofilms, which are usually challenging to effectively inhibit. Cytotoxicity screening revealed that 
the commercial essential oils halved fibroblast proliferation at concentrations lower than those 
required to inhibit C. albicans growth. Further investigation on the effect of these agents against 
mammalian cells is however warranted before any in vivo application. The antifungal potential 
of these essential oils could be a future therapeutic for topical candidosis as an option to overcome 
emerging antifungal drug resistance.  
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